Adalimumab biosimilar copay caps ran about $1200 to $3000 a year vs up to $14,000 for Humira, a report found.
Manufacturer copayment (copay) assistance for adalimumab biosimilars tops out at roughly $1200 to $3000 a year when a limit is disclosed or a program exists at all, compared with up to $14,000 for Humira, according to a brief report published in the Journal of the American Academy of Dermatology.1
Adalimumab biosimilar co-pay caps ran about $1200 to $3000 a year vs up to $14,000 for Humira, a report found. | Image credit: Luluraschi - stock.adobe.com

Adalimumab (Humira; AbbVie), first approved in 2002 as the first fully human antitumor necrosis factor α monoclonal antibody, became widely used across dermatologic and nondermatologic conditions. From 2023 to 2024, numerous adalimumab biosimilars entered the US market, and 3 of the largest pharmacy benefit managers (PBMs) shifted their formularies to favor biosimilars and exclude Humira. The researchers noted that, although biosimilars were expected to improve affordability and access, net prices remained high and affordability was limited during the first year of US biosimilar entry. They added that early clinical experience suggests transitions may disrupt treatment continuity and that switching can introduce anxiety and uncertainty, particularly for patients who have achieved stable disease control.
Uptake during that first year was slow. A cross-sectional analysis of national prescription data published in JAMA Health Forum found that the biosimilar share of adalimumab prescriptions rose from 0.03% in the first quarter of 2023 to 1.35% in the fourth quarter.2 Adalimumab-adbm, the only biosimilar designated interchangeable at the time, accounted for 2.35% of biosimilar prescriptions in 2023. In the fourth quarter of that year, Humira's net price per prescription ($2798) was lower than those of the 3 biosimilars with reported net sales ($3452-$4793).
To gauge how these transitions affect access, the researchers cataloged manufacturer-sponsored patient assistance programs for each FDA-approved adalimumab biosimilar and compared them with the programs offered for Humira.1 They drew on manufacturer websites, publicly available program materials, and direct communication with manufacturers, collecting data from February 27, 2026, to March 1, 2026. The report's comparison of annual assistance caps covered 10 biosimilars.
Because the analysis examined programs rather than patients, it did not include a patient population or demographic data. The researchers found that the FDA-approved biosimilars share similar indications, dosing, and formulations with Humira, with no clinically meaningful differences in efficacy or safety identified. They also noted that manufacturer copay assistance programs primarily apply to commercially insured patients and may not be available to people with government-sponsored insurance.
The differences emerged in financial support. Humira's program provided up to $14,000 annually in copay assistance, whereas biosimilar programs carried caps of approximately $1200 to $3000, had undisclosed limits, or did not exist. Of the 10 biosimilars charted, 4 had publicly disclosed annual caps, 5 had limits that were not publicly available, and the program for adalimumab-afzb had been discontinued. Adalimumab-adbm was among the products without a publicly disclosed cap.
Several programs reported that assistance varied by insurance plan rather than following a fixed annual maximum, and attempts to obtain estimated out-of-pocket costs from manufacturers were often unsuccessful, limiting patients' ability to anticipate expenses before starting treatment. The researchers suggested the gap may partly reflect formulary changes influenced by manufacturer rebates, in which insurance coverage may not always align with patient out-of-pocket costs. When copay assistance does not count toward a patient's deductible, they wrote, patients can reach the assistance limit faster and face a growing financial burden over time. The researchers concluded that patients with greater financial limitations and other barriers to care may be disproportionately affected by the current structure of biosimilar assistance programs.
"Moving forward, greater transparency and patient assistance programs that provide increased financial support are needed to ensure more affordable access to these disease-altering therapies," the authors wrote.
The report was a brief snapshot of program terms gathered over 3 days, relied on public materials and manufacturer responses, and did not measure what patients actually paid or whether lower assistance caps led patients to discontinue therapy. Program terms can change over time, and limits that manufacturers did not disclose could not be assessed.
Still, the findings point to a gap between formulary savings and patient affordability. A biosimilar preferred on a PBM formulary does not guarantee a manageable out-of-pocket bill when manufacturer support is limited or opaque. For payers and PBMs that moved patients off Humira, and for biosimilar manufacturers, the report suggests that formulary position and interchangeability designations alone may not secure affordable access in dermatology; the size and transparency of assistance programs also shape what patients pay.
References
1. Alomary SA, Baker NJ, Alladeen A, et al. Adalimumab biosimilars and access barriers in dermatology. J Am Acad Dermatol. 2026;95(4):1218-1221. doi:10.1016/j.jaad.2026.06.119
2. Rome BN, Bhaskar A, Kesselheim AS. Use, spending, and prices of adalimumab following biosimilar competition. JAMA Health Forum. 2024;5(12):e243964. doi:10.1001/jamahealthforum.2024.3964
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.